References

1. Fine P.E.M.: Herd immunity: history, theory, practice. Epidemiol Rev  1993; 15:265-302.

2. Fox J.P., Elveback L., Scott W., et al: Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol  1971; 94:179-189.

3. Anderson R.M.: The concept of herd immunity and the design of community-based immunization programmes. Vaccine  1992; 10:928-935.

4. Jenner E.: The Origin of the Vaccine Inoculation.  London, Shury, 1801.

5. Dubos R., Dubos J.: The White Plague.  London, Victor Gollancz, 1953.

6. Salmon D.A., Teret S.P., Macintyre C.R., et al: Compulsory vaccination and conscientious or philosophical exemptions: past present and future. Lancet  2006; 367:436-442.

7. Farr W.: Second Annual Report of the Registrar-General of Births, Deaths, and Marriages in England.  London, Her Majesty's Stationery Office, 1840.

8. Topley W.W.C., Wilson G.S.: The spread of bacterial infection: the problem of herd immunity. J Hyg  1923; 21:243-249.

9. Greenwood M.: Epidemics and Crowd Diseases.  London, Williams & Norgate, 1935.

10.  In: Dowdle W.R., Hopkins D.R., ed. The Eradication of Infectious Diseases,  Chichester, UK: John Wiley; 1998.

10a. Fine P.E.M., Eames K., Heymann D.L.: “Herd immunity”: a rough guide. Clin Infect Dis  2011; 52:911-916.

11. Hamer W.H.: Epidemic disease in England: the evidence of variability and of persistency of type. Lancet  1906; 1:733-739.

12. Anderson R.M., May R.M.: Infectious Diseases of Humans: Dynamics and Control.  Oxford, UK, Oxford University Press, 1991.

13. Macdonald G.: The Epidemiology and Control of Malaria.  London, Oxford University Press, 1957.

14. Dietz K.: The estimation of the basic reproduction number for infectious diseases. Stat Methods Med Res  1993; 2:23-41.

15. Hethcote H.W.: Measles and rubella in the United States. Am J Epidemiol  1983; 117:2-13.

16. Dietz K.: Transmission and control of arbovirus diseases.   In: Ludwig D., Cooke K.L., ed. Epidemiology,  Philadelphia, PA: Society for Industrial and Applied Mathematics; 1975:104-121.

17. Fine P.E.M.: The interval between successive cases of an infectious disease. Am J Epidemiol  2003; 158:1039-1047.

18. Mills C.E., Robins J.M., Lipsitch M.: Transmissibility of 1918 pandemic influenza. Nature  2004; 432:904-906.

19. Ferguson N.M., Cummings D.A., Cauchemez S., et al: Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature  2005; 437:209-214.

20. Schenzle D.: An age-structured model of pre- and post-vaccination measles transmission. IMA J Math Appl Med Biol  1984; 1:169-191.

21. Anderson R.M., May R.M.: Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg (Camb)  1985; 94:365-436.

22. Katzmann W., Dietz K.: Evaluation of age-specific vaccination strategies. Theor Popul Biol  1984; 25:125-137.

23. Knox E.G.: Strategy for rubella vaccination. Int J Epidemiol  1980; 9:13-23.

24. Anderson R.M., Crombie J.A., Grenfell B.T.: The epidemiology of mumps in the UK: preliminary study of virus transmission, herd immunity and the potential impact of vaccination. Epidemiol Infect  1987; 99:65-84.

25. May R.M., Anderson R.M.: Spatial heterogeneity and the design of immunization programmes. Math Biosci  1984; 72:83-111.

26. Hethcote H.W., Van Ark J.W.: Epidemiological models for heterogeneous populations: proportionate mixing, parameter estimation, and immunization programs. Math Biosci  1987; 84:85-118.

27. Grenfell B.T., Bjornstad O.N., Kappey J.: Travelling waves and spatial hierarchies in measles epidemics. Nature  2001; 414:716-723.

28. Strebel P.M., Cochi S.L.: Waving goodbye to measles. Nature  2001; 414:695-696.

29. Anderson R.M., May R.M.: Spatial, temporal, and genetic heterogeneity in host populations and the design of immunization programmes. IMA J Math Appl Med Biol  1984; 1:233-266.

30. Smith P.G., Rodrigues L.C., Fine P.E.M.: Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol  1984; 13:137-153.

31. Longini I.M., Halloran M.E., Nizam A.: Model-based estimation of vaccine effects from community vaccine trials. Stat Med  2002; 21:481-495.

32. World Health Assembly : Official Records of the World Health Organization: 1959: Resolutions and Decisions of the 12th World Health Assembly (WHA 12.54).  Geneva, World Health Organization, 1959.

33. Fenner F., Henderson D.A., Arita I., et al: Smallpox and Its Eradication.  Geneva, World Health Organization, 1988.

34. Gani R., Leach R.: Transmission potential of smallpox in contemporary populations. Nature  2001; 414:748-751.

35. Arita I., Wickett J., Fenner F.: Impact of population density on immunization programmes. J Hyg  1986; 96:459-466.

36. Henderson D.A.: Epidemiology in the global eradication of smallpox. Int J Epidemiol  1972; 1:25-30.

37. Hammerlund E., Lewis M.W., Hansen S.G., et al: Duration of antiviral immunity after smallpox vaccination. Nature Med  2003; 9:1131-1137.

38. Taub D.D., Ershler W.B., Janowski M., et al: Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med  2008; 121:1058-1064.

39. Henderson D.A.: The looming threat of bioterrorism. Science  1999; 283:1279-1282.

40. Enserink M.: How devastating would a smallpox attack really be?. Science  2002; 297:50-51.

41. House T., Hall I., Danon L., et al: Contingency planning for a deliberate release of smallpox in Great Britain: the role of geographical scale and contact structure. BMC Infect Dis  2010; 10:25.

42. Fauci A.S.: Smallpox vaccination policy: the need for a dialogue. N Engl J Med  2002; 346:1319-1320.

43. Couch R.B., Winokur P., Edwards K.M.National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group: Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J Infect Dis  2007; 195:826-832.

44. Nokes D.J., Anderson R.M.: Measles, mumps, and rubella vaccine: what coverage to block transmission?. Lancet  1988; 2:1374.

45. Farrington C.P.: Modelling forces of infection for measles, mumps, and rubella. Stat Med  1990; 9:953-967.

46. Fine P.E.M., Clarkson J.A.: Measles in England and Wales, I: an analysis of factors underlying seasonal patterns. Int J Epidemiol  1982; 11:5-14.

47. Fine P.E.M., Clarkson J.A.: Measles in England and Wales, II: the impact of the measles vaccination programme on the distribution of immunity in the population. Int J Epidemiol  1982; 11:15-25.

48. Black F.L.: The role of herd immunity in the control of measles. Yale J Biol Med  1982; 55:351-360.

49. Sencer D.J., Dull H.B., Langmuir A.D.: Epidemiologic basis for eradication of measles in 1967. Public Health Rep  1967; 82:253-256.

50. Hopkins D.R., Hinman A.R., Koplan J.P., et al: The case for global measles eradication. Lancet  1982; 1:1396-1398.

51. Henderson D.A.: Global measles eradication. Lancet  1982; 2:208.

52. World Health Organization : Measles Mortality Reduction and Regional Elimination: Strategic Plan, 2000–2005.  (WHO/V&B/01.13)Geneva, World Health Organization, 2001.

53. de Quadros C.A.: Can measles be eradicated globally?. Bull WHO  2004; 82:134-138.

54. Heymann D.L., Fine P.E.M., Griffiths U.K., et al: Measles eradication: the past is prologue. Lancet  2010; 376:1719-1720.

55. Yorke J.A., Nathanson N., Pianigiani G., et al: Seasonality and the requirements for perpetuation and eradication of viruses in populations. Am J Epidemiol  1979; 109:103-123.

56. Fahlgren K.: Two doses of MMR vaccine: sufficient to eradicate measles, mumps, and rubella?. Scand J Soc Med  1988; 16:129-135.

57. de Quadros C.A., Izurieta H., Venczel L., et al: Measles eradication in the Americas: progress to date. J Infect Dis  2004; 189:S227-S235.

58. Otten M., Kezaala R., Fall A., et al: Public health impact pf accelerated measles control in the WHO African Region 2000–03. Lancet  2005; 366:832-839.

59. Centers for Disease Control and Prevention : Measles, rubella, and congenital rubella syndrome: United States and Mexico, 1997–1999. MMWR Morb Mortal Wkly Rep  2000; 49:1048-1050.1059

60. Gay N., Ramsay M., Cohen B., et al: The epidemiology of measles in England and Wales since the 1994 vaccination campaign. Commun Dis Rep  1997; 7:17-21.

61. Panum P.L.: Observations made during the epidemic of measles on the Faroe Islands in the year 1846.  Delta Omega Society;1940.

62. Whittle H., Aaby P., Samb B., et al: Poor serologic responses five to seven years after immunization with high and standard titer measles vaccines. Paediatr Infect Dis J  1999; 18:53-57.

63. Mulholland E.K.: Measles and pertussis in developing countries with good vaccine coverage. Lancet  1995; 345:305-307.

64. Anderson R.M., May R.M.: Vaccination against rubella and measles: quantitative investigation of different policies. J Hyg (Camb)  1983; 90:259-325.

65. van Druten J.A.M., de Boo T., Plantinga A.D.: Measles, mumps, and rubella: control by vaccination. Dev Biol Stand  1986; 65:53-63.

66. Panagiotopoulos T., Antoniadou I., Valassi-Adam E.: Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ  1999; 319:1462-1467.

67. Ueda K., Nishida Y., Oshima K., et al: An explanation for the high incidence of congenital rubella syndrome in Ryukyu. Am J Epidemiol  1978; 107:344-351.

68. Gao L., Hethcote H.: Simulations of rubella vaccination strategies in China. Math Biosci  2006; 202:371-385.

69.  World Health Organization. Immunization profile: China. http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm?C='chn' (accessed 04 April 2012)

70. Meissner H.C., Reef S.E., Cochi S.: Elimination of rubella from the United States: a milestone on the way to global elimination. Pediatrics  2006; 117:933-935.

71. Kim Farley R., Bart S., Stetler H., et al: Clinical mumps vaccine efficacy. Am J Epidemiol  1985; 121:593-597.

72. Sullivan K.M., Halpin T.J., Marks J.S., et al: Effectiveness of mumps vaccine in a school outbreak. Am J Dis Child  1985; 139:909-912.

73. Savage E., Ramsay M., White J., et al: Mumps outbreaks across England and Wales in 2004: observational study. BMJ  2005; 330:1119-1120.

74. Seward J.F., Watson B.M., Peterson C.L., et al: Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA  2002; 287:606-611.

75. Yih W.K., Brooks D.R., Lett S.M., et al: The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health  2005; 5:68.

76. Hall S., Seward J., Jumaan A.O., et al: Second varicella infections: are they more common than previously thought?. Pediatrics  2002; 109:1068-1073.

77. Thomas S.L., Wheeler J.G., Hall A.J.: Contacts with varicella or with children and protection against zoster in adults: a case-control study. Lancet  2002; 360:678-682.

78. Brisson M., Gay N.J., Edmunds W.J., et al: Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine  2002; 20:2500-2507.

79. Whitley R.J.: Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. J Infect Dis  2005; 191:1999-2001.

80. Edmunds W.J., Brisson M.: The effect of vaccination on the epidemiology of varicella-zoster virus. J Infect  2002; 44:211-219.

81. Halloran M.E.: Epidemiologic effects of varicella vaccination. Infect Dis Clin North Am  1996; 3:631-655.

82. Rimland D., Moanna A.: Increasing incidence of herpes zoster among veterans. Clin Infect Dis  2010; 50:1000-1005.

83. Oxman M.N., Levin M.J., Johnson G.R., et al: A vaccine to prevent Herpes zoster and postherpetic neuralgia in older adults. N Engl J Med  2005; 352:2271-2284.

84.  Centers for Disease Control and Prevention. ACIP Prevention of Herpes Zoster. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm?s_cid=rr5705a1_e (accessed 05 April 2012)

85.  Department of Health (UK). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_114908.pdf (accessed 05 April 2012)

86. Bayer O., Heininger U., Heiligensetzer C., et al: Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine  2007; 25:6655-6660.

87. Bruer J.: Varicella vaccination for healthcare workers. Brit Med J  2005; 330:433-434.

88. Preziosi M.P., Yam A., Wassilak S.G., et al: Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol  2002; 155:891-896.

89. Trollfors B., Taranger J., Lagergard T., et al: Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J  1998; 17:196-199.

90. Fine P.E.M., Clarkson J.A.: The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet  1982; 2:666-669.

91. Grenfell B.T., Anderson R.M.: Pertussis in England and Wales: an investigation of transmission dynamics and control by mass vaccination. Proc R Soc Lond B Biol Sci  1989; 236:213-253.

91a. Kretzschmar M., Teunis P.F.M., Pebody R.G.: Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries. PLoS Med  2010; 7(6):e1000291

92. Fine P.E.M., Clarkson J.A.: Reflections on the efficacy of pertussis vaccines. Rev Infect Dis  1987; 9:866-883.

93. Edwards K.M., Decker M.D.: Pertussis vaccines.   In: Plotkin S., Orenstein W., Offit P., ed. Vaccines, 21. 5th. China: Saunders Elsevier; 2008:467-517.

94. Farrington C.P.: The measurement of age-specific vaccine efficacy. Int J Epidemiol  1992; 21:1014-1020.

95. Cherry J.D.: The role of Bordetella pertussis infections in adults in the epidemiology of pertussis. Dev Biol Stand  1997; 89:181-186.

96. Fine P.E.M.: Epidemiological considerations for whooping cough eradication.   In: Wardlaw A.L., Parton R., ed. Pathogenesis and Immunity to Pertussis,  Chichester, UK: John Wiley; 1988:451-467.

97. Fine P.E.M.: Implications of different study designs for the evaluation of acellular pertussis vaccines. Dev Biol Stand  1997; 89:123-133.

98.  In: Brown F., Greco D., Mastrantonio P., et al ed. Pertussis Vaccine Trials,  Basel, Switzerland: Karger; 1997.

99. Fine P.E.M.: Adult pertussis: a salesman's dream, and an epidemiologist's nightmare. Biologicals  1997; 25:195-198.

100. Edwards K.M.: Is pertussis a frequent cause of cough in adolescents and adults? should routine pertussis immunization be recommended?. Clin Infect Dis  2001; 32:1698-1699.

101. Ward J.I., Cherry J.D., Chang S.J, et al: Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med  2006; 353:1555.

102. Committee on Infectious Diseases : Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics  2006; 117:965-978.

103. Centers for Disease Control and Prevention : Advisory Committee on Immunization Practice recommends adult vaccination with new tetanus, diphtheria and pertussis vaccine (Tdap),  2005. Press release; 9 Nov

103a.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6041a4.htm?s_cid=mm6041a4_w

104. Coudeville L., Van Rie A., Getsios D., et al: Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS ONE  2009; 4(7):e6284.

105. Healy C.M., Rench M.A., Baker C.J.: Implementation of cocooning against pertussis in a high risk population. Clin Infect Dis  2011; 52:157-162.

106. Miller L.W., Older J.J., Drake J., et al: Diphtheria immunization: effect upon carriers and the control of outbreaks. Am J Dis Child  1972; 123:197-199.

107. Jones E.E., Kim-Farley R.G., Algunaid M., et al: Diphtheria: a possible foodborne outbreak in Hodeida, Yemen Arab Republic. Bull World Health Organ  1985; 63:287-293.

108. Marcuse E.K., Grand M.G.: Epidemiology of diphtheria in San Antonio, Texas, 1970. JAMA  1973; 224:305-310.

109. Simonson O., Kjeldsen K., Bentzon M.W., et al: Susceptibility to diphtheria in populations vaccinated before and after elimination of indigenous diphtheria in Denmark. Acta Pathol Microbiol Immunol Scand  1987; 95:225-231.

110. McQuillan G.M., Kruszon-Moran D., Deforest A., et al: Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med  2002; 136:660-666.

111. Maple P.A., Jones C.S., Wall E.C., et al: Immunity to diphtheria and tetanus in England and Wales. Vaccine  2000; 19:167-173.

112. Christenson B., Hellstrom U., Sylvan S.P., et al: Impact of a vaccination campaign on adult immunity to diphtheria. Vaccine  2000; 19:1133-1140.

113. Chen R.T., Broome C.V., Weinstein R.A., et al: Diphtheria in the United States, 1971–1981. Am J Public Health  1985; 75:1393-1397.

114. Doull J.A., Lara H.: The epidemiologic importance of diphtheria carriers. Am J Hyg  1925; 5:508-529.

115. Bergamini M., Fabrizi P., Pagani S., et al: Evidence of increased carriage of Corynebacterium spp. in healthy individuals with low antibody titres against diphtheria toxoid. Epidemiol Infect  2000; 125:105-112.

116. Moxon E.R., Anderson P.: Meningitis caused by Haemophilus influenzae in infant rats: protective immunity and antibody priming by gastrointestinal colonization with Escherichia coli. J Infect Dis  1979; 140:471-478.

117. Dagan R., Fraser D., Roitman M., et al: Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. Vaccine  1998; 17:134-141.

118. Adegbola R.A., Secka O., Lahai G., et al: Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with Hib conjugate vaccine: a prospective study. Lancet  2005; 366:144-150.

119. Peltola H., Aavitsland P., Hansen K.G., et al: Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis  1999; 179:223-229.

120. Trotter C.L., Ramsay M.E., Slack M.P.E.: Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health  2003; 6:55-58.

121. Soininen A., Pursiainen H., Kilpi T., et al: Natural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young children. J Infect Dis  2001; 184:569-576.

122. Kyaw M.H., Lynfield R., Schaffner W., et al: Effect of introduction of the pneumococcal vaccine on drug resistant Streptococcus pneumoniae. N Engl J Med  2006; 354:1455-1463.

123. Vestrheim D.F., Hoiby E.A., Bergsaker M.R., et al: Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 schedule. Vaccine  2010; 28:2214-2221.

124. Hanna J.N., Humphreys J.L., Murphy D.M.: Invasive pneumococcal disease in indigenous people in north Queensland: an update, 2005–2007. Med J Aust  2008; 189:43-46.

125. Singleton R.J., Hennessy T.W., Bulkow L.R., et al: Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA  2007; 297:1784-1792.

126. Musher D.M.: Pneumococcal vaccine-direct and indirect ('herd') effects. N Engl J Med  2006; 354:1522-1524.

127. Cutts F.T., Zaman S.M., Enwere G., et al: Efficacy of nine-valent pneumococcal vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double-blind, placebo-controlled trial. Lancet  2005; 365:1139-1146.

128. Newell K.W., Duenas Lehman A., et al: The use of toxoid for the prevention of tetanus neonatorum: final report of a double-blind controlled field trial. Bull World Health Organ  1966; 35:863-871.

129. Melnick J.L.: Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull World Health Organ  1978; 56:21-38.

130. Fine P.E.M., Carneiro I.A.M.: Transmissibility and persistence of oral polio vaccine viruses. Am J Epidemiol  1999; 150:1001-1021.

131. Nkowane B.M., Wassilak S.G.F., Orenstein W.A., et al: Vaccine-associated paralytic poliomyelitis, United States: 1973 through 1984. JAMA  1987; 257:1335-1340.

132. Bottiger M.: A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis  1987; 19:595-601.

133. Hovi T., Cantell K., Huovilainen A., et al: Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet  1986; 1:1427-1432.

134. Schaap G.J., Bijkerk H., Coutinho R.A.: The spread of wild polio virus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol  1984; 29:124-140.

135. Grassly N.C., Jafari H., Bahl S., et al: Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis  2009; 200:794-801.

136. Fine P.E.M.: Polio: measuring the protection that matters most. J Infect Dis  2009; 200:673-675.

137. Sutter R.W., John T.J., Jain H., et al: Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet  2010; 376:1682-1688.

138. Kew O.M., Sutter R.W., de Gourville E., et al: Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol  2005; 59:587-635.

139. Wringe A., Fine P.E.M., Sutter R.W., et al: Estimating the extent of vaccine-derived poliovirus infection. PLoS ONE  2008; 3:1-10.

140. Fine P.E.M., Sutter R.W., Orenstein W.A.: Stopping a polio outbreak in the post-eradication era. Dev Biol (Basel)  2001; 105:129-147.

141. John T.J., Vashishtha V.M.: Eradication of vaccine polioviruses: why, when & how?. Indian J Med Res  2009; 130:491-494.

142. Centers for Disease Control and Prevention : Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep  2005; 54(RR-8):1-40.

143. Monto A.S., Davenport F.M., Napier J.A., et al: Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis  1970; 22:16-25.

144. Rudenko L.G., Slepushkin A.N., Monto A.S., et al: Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis  1993; 168:881-887.

145. Glezen W.P.: Herd protection against influenza. J Clin Virol  2006; 37:237-243.

146. King Jr J.C., Stoddard J.J., Gaglani M.J., et al: Effectiveness of school-based influenza vaccination. N Engl J Med  2006; 355:2423-2432.

147. Reichert T.A., Sugaya N., Fedson D.S., et al: The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med  2001; 344:889-896.

148.  Now Public. WHO's declaration of H1N1 pandemic: swine flu virus. http://www.nowpublic.com/health/full-text-whos-declaration-h1n1-pandemic-swine-flu-virus (accessed 05 April 2012)

149. Ferguson N.M., Cummings D.A.T., Cauchemez S., et al: Strategies for mitigating an influenza pandemic. Nature  2006; 442:448-452.

150. Longini I.M., Nizam A., Xu S., et al: Containing pandemic influenza at source. Science  2005; 309:1083-1087.

151. Longini I.M., Halloran M.E.: Strategy for distribution of influenza vaccine to high risk groups and children. Am J Epidemiol  2005; 161:303-306.

152.  WHO Pandemic influenza preparedness and response: WHO guidance document. Geneva: Global Influenza Programme, WHO; 2009. http://whqlibdoc.who.int/publications/2009/9789241547680_eng.pdf (accessed 05 April 2012)

153. Centers for Disease Control and Prevention : Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR  2010; 59:1-62.

154. Villa L.L., Costa R.L.R., Petta C.A., et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol  2005; 6:271-278.

155. Garnett G.P.: Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis  2005; 191(suppl 1):S97-S106.

156. Dasbach E.J., Elbasha E.H., Insinga R.P.: Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev  2006; 28:88-100.

156a.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm

157. Brotherton J.M., Kaldor J.M., Garland S.M.: Monitoring the control of human papillomavirus infection and related diseases in Australia: towards a national HPV surveillance strategy. Sexual Health  2010; 7:310-319.

158. Donovan B., Franklin N., Guy R., et al: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis  2011; 11:39-44.

159. Kochi A., Nunn P., Dye C., et al: Global burden of disease. Lancet  1997; 350:142.

160. Fine P.E.M., Carneiro I.A.M., Milstein J.B., et al: Issues Relating to the Use of BCG in Immunization Programmes.  (WHO/V&B/99.23).Geneva, World Health Organization, 1999.

161. Fine P.E.M., Sterne J.A.C., Ponnighaus J.M., et al: Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet  1994; 344:1245-1249.

162. Styblo K., Meijer J.: Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle  1976; 57:17-43.

163. Aronson N.E., Santosham M., Comstock G.W., et al: Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA  2004; 291:2086-2091.

164. Sutherland I., Lindgren I.: The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle  1979; 60:225-231.

165. Soysal A., Millington K.A., Bakir M., et al: Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet  2005; 366:1443-1451.

166. Trunz B.B., Fine P.E.M., Dye C.: Effect of BCG vaccination on childhood tuberculous meningitis and military tuberculosis worldwide: a metaanalysis and assessment of cost-effectiveness. Lancet  2006; 367:1175-1182.

167. Fine P.E.M.: Variation in protection by BCG: implications of and for heterologous immunity. Lancet  1995; 346:1339-1345.

168. Fine P.E.M., Vynnycky E.: The effect of heterologous immunity upon the apparent efficacy of (eg BCG) vaccines. Vaccine  1998; 16:1923-1928.

169. Merle C.S., Cunha S.S., Rodrigues L.C.: BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines  2010; 9:209-222.

170. Brooker S., Bethony J.M., Rodrigues L.C., et al: Epidemiologic, immunologic and practical considerations in developing and evaluating a human hookworm vaccine. Expert Rev Vaccines  2005; 4:35-50.

171. Good M.F., Xu H., Wykes M., et al: Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Ann Rev Immunol  2005; 23:69-99.

172. Smith T.A., Chitnis N., Briët O.J., et al: Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum. Trends Parasitol  2011; 27:190-196.

173. Jariwala A.R., Oliveira L.M., Diemert D.J., et al: Potency testing for the experimental Na-GST-1 hookworm vaccine. Expert Rev Vaccines  2010; 9:1219-1230.

174. Halloran M.E., Haber M., Longini I.M., et al: Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol  1991; 133:323-331.

175. Bjune G., Hoiby E.A., Gronnesby J.K., et al: Effects of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet  1991; 338:1093-1096.

176. Ali M., Emch M., von Seidlin L., et al: Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet  2005; 366:44-49.

177. Patel M.M., Tate J., Cortese M., et al: The impact of indirect benefits of vaccination on postlicensure vaccine effectiveness estimates: a scenario analysis. Vaccine  2010; 28:7987-7992.

178. John T.J., Samuel R.: Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol  2000; 16:601-606.

179. Klock L.E., Rachelefsky G.S.: Failure of rubella herd immunity during an epidemic. N Engl J Med  1973; 288:69-72.

180.  Nguipdop-Djono P, Thomas SL, Fine PEM. Correlates of vaccine-induced protection: methods and implications. WHO/IVB/10.00, in press.

181. Orenstein W.A., Hinman A.R.: The immunization system in the United States—the role of school immunization laws. Vaccine  1999; 17(suppl):S19-S24.